Rating Change
UBS analysts initiated coverage on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) with a rating of Buy on October 12, 2026.
new coverageNASDAQ:PTGX
UBS Initiates Coverage on Protagonist Therapeutics, Inc. (PTGX) with Buy
UBS analysts initiated coverage on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) with a rating of Buy on October 12, 2026.
At publication ·
What changed
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) · new coverage
- Firm
- UBS
- Rating
- Buy
- Price at event
- $144.85
- Market capitalization
- $5.8B
At a glance
Key takeaways
- UBS initiated Buy coverage on Protagonist Therapeutics (PTGX) on October 12, 2026, as the stock trades at $144.85 with a $5.8B market capitalization.
Market Context
Protagonist Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $144.85 with a market capitalization of $5.8B.
Analyst coverage from UBS provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Protagonist Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Protagonist Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Buy | N/A |
| Sep 01, 2026 | BMO Capital | Outperform | N/A |
| Sep 01, 2026 | Barclays | Overweight | N/A |
| Aug 31, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 31, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PTGX Stock Page
Frequently Asked Questions
What does the Buy rating mean for PTGX?
A rating of Buy from UBS reflects the analyst's outlook on Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PTGX forecast page.